Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLC1401 combined with CDK4/6 or mTOR inhibitors in advanced breast cancer
NCT07173556Phase 2Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Sep 2025
- Primary completion
- Feb 2027
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of QLC1401 in breast cancer, sponsored by Qilu Pharmaceutical. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
QLC1401
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07173556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07173556.